Name: Laura Mundschau
Kasman
Office
Address: Medical
University of SC Phone:
(843) 792-8117
BSB-201,
PO Box 250504
Department
of Microbiology & Immunology
173
Ashley Avenue, Charleston SC 29425
Education:
Ripon
College 1981-1983 transferred Biology
Ripon,
WI
University
of Wisconsin 1983-1985 B.S. Agriculture
Madison,
WI
University
of Wisconsin 1985-1987 M.S. Muscle
Biology
Madison,
WI
Harvard
University 1987-1992 Ph.D. Virology
Internships:
None
Residencies or
Post Doctoral:
Boston University School of Medicine 1992
Massachusettes
Institute of Technology, Cambridge, MA 1992-1994
University
of Georgia – Athens, GA 1995-1996
University
of California – Berkeley, CA 1998-1999
Medical
University of South Carolina, Charleston, SC 1999-2000
Specialty/Board
Certification:
N/A
Licensure:
None
Military
Service:
None
Faculty
Appointments:
2000-2002
Research Assistant Professor MUSC Microbiology &
Immunology
2002-Present
Assistant Professor MUSC Microbiology &
Immunology
Administrative
Appointments:
Microbiology
and Immunology Graduate Program Coordinator
Hospital
Appointments/Privileges:
None
Other
Experiences:
Scientific Consultant, Packerland
Packing Company, Green Bay, WI June-August 1985
Staff
Scientist, Praecis Pharmaceuticals, Inc., Cambridge MA January1994 –August 1995
Instructor,
Metropolitan College of Boston University , Boston, MA 1992
Membership in
professional/scientific societies:
National Societies
American Society of Gene
Therapy 2000
American Society For
Microbiology 2000-present
American Society For
Virology 2002-present
Awards,
Honors, Membership in Honorary Societies:
1990-1991 Ryan
Fellowship
1989 Baxter
Foundation Fellowship
1985 Valedictorian,
College of Agriculture, University of Wisconsin-Madison
Academic
Committee Activities:
Medical
School Progress Committee 2002-present
College
of Graduate Studies Admissions Committee 2007-present
FYC
Steering Committee 2007-present
Graduate
Council 2007-present
Microbiology
and Immunology Graduate Committee (Chair)
2007-present
Thesis
committees of PhD students: Lori
Hudson
Jennifer Cook
Mark Pilgrim
Iris Moralez
Masters
degree students:
Mary Bruorton
Thomas Shaak,
Christopher
Marshall
Major Teaching
Responsibilities (Current):
MBIM
614G Immunity
MBIM
785 Microbiology and Spring Immunology Selective
Major Clinical
Interests and Responsibilities:
N/A
Lectures and
Presentations:
Submitted
presentations (e.g., abstract or paper presentations)
Kasman,
L.M., Werner, P., Westwater, C., Schofield,
D., Hoel. B, Dolan, J., Schmidt. M., and Norris, J.S. (June 2000.) LADS: Treatment of experimental infections in
embryonated hen eggs and mice. Evergreen
International Phage Meeting. Montreal,
Quebec
Westwater,
C., Schofield, D., Kasman, L.M., Hoel. B, Werner, P., Schmidt. M.,
Dolan, J., and Norris, J.S. (June 2000.) Prokaryotic Gene therapy for the treatment of bacterial
infections. Evergreen International Phage Meeting. Montreal, Quebec
Westwater,
C., Schofield, D., Kasman, L.M., Hoel. B, Werner, P., Schmidt. M., Dolan,
J., and Norris, J.S. (June 2000.) Gene
therapeutic for the treatment of bacterial infections. Evergreen International
Phage Meeting. Montreal, Quebec
Kasman,
L. M.
(May 2001.) Bacteriophage lysogeny in the mammalian gut. (Abstract M-2) National Meeting of the American Society for
Microbiology. Orlando FL.
Westwater,
C., Schofield, D., Kasman, L.M., Werner, P., Hoel. B, Schmidt. M.,
Dolan, J., and Norris, J.S. (May 2001) Prokaryotic gene therapy for the
treatment of bacterial infections. (Abstract M-8) ) National Meeting of the American Society for
Microbiology. Orlando FL.
Schofield,
D., Westwater, C., Kasman, L.M., Hoel. B, Werner, P., Schmidt. M.,
Dolan, J., and Norris, J.S. (May 2001) Gene therapeutics for the treatment of
bacterial infections. (Abstract M-8) )
National Meeting of the American Society for Microbiology. Orlando FL.
Bruorto,
M., Pilgrim, M., London. L., London, S.D., and Kasman, L.M. (April 2005)
MCMV-induced xerostomia in mice. 10th International Cytomegalovirus/Betaherpesvirus
Workshop
April
24-28, 2005. Williamsburg, Virginia
Joseph C. Brown, Jinxue Wang, Laura
Kasman*, Vivian Haley-Zitlin, and Xiuping Jiang. (May 2008) An in vivo study of the effect of muscadine
grape skin powder on the growth and bacterial colonization of mice infected
with Helicobacter pylori. National
Meeting of the American Society for Microbiology, Orlando FL.
Recent
Oral presentations
Redefining
MOI. Microbiology and Immunology
Departmental Seminar Series. January 19,
2002.
GM
genes in herpes stromal keratitis.
Opthalmology Journal Club, Storm Eye Institute, January 16, 2003
Inflammation
and MCMV infections: Friend or Foe?
Microbiology and Immunology Departmental Seminar Series. August, 2005.
HDAci
and adenovirus gene therapy of prostate cancer.
Microbiology and Immunology Departmental Seminar Series. September 2006.
Extramural
Professional Activities:
NSF grant reviewer for Graduate
Fellowship Program 2005
Ad hoc grant reviewer for the United
States-Israel Binational Science Foundation 2005
Ad hoc grant reviewer for the STCU
Program (U.S. State Department) 2007
Reviewer Mol. Ther. of Cancer
Reviewer Clinical Opthalmology
Community
Service:
State
Science Fair Judge, Athens, GA April 1996.
Lowcountry
Science Fair Judge, Charleston, SC,
2000, 2004, 2006
Publications:
(1)
Mundschau, L. J. and D. V Faller.
(1991) BALB/c-3T3 fibroblasts resistant to growth inhibition by
interferon exhibit aberrant platelet-derived growth factor, epidermal growth
factor, and fibroblast growth factor signal
transduction. Mol. Cell. Biol. 11: 3148-3154.
(2)
Quinones, M. A., L. J. Mundschau, J. B. Rake, and D. V. Faller.
(1991) Dissociation of
platelet-derived growth factor (PDGF) receptor autophosphorylation from other PDGF-mediated second messenger events. J.
Biol. Chem. 266: 14055-14063.
(3)
Mundschau L.J. and Faller D.V.
(1992) Oncogenic ras induces an inhibitor of
double-stranded RNA-dependent eukaryotic initiation factor-2 kinase
activation. J. Biol. Chem. 267: 23092-23098.
(4)
Mundschau, L. J., L. W. Forman, and D. V. Faller. (1994)
Platelet-derived growth factor (PDGF) induction of egr-1 is independent of PDGF receptor autophosphorylation on
tyrosine. J. Biol. Chem. 269: 16137-16142.
(5)
Faller, D.V., L. J. Mundschau,
L. W. Forman, and M.A. Quinones. (1994) v-mos suppresses platelet-derived growth
factor (PDGF) type- receptor
autophosphorylation and inhibits PDGF-BB-mediated signal transduction. J.
Biol. Chem. 269: 5022-5029.
(6)
Mundschau, L. J. and D. V. Faller.
(1994) Endogenous inhibitors of the
dsRNA-dependent eIF-2 protein kinase PKR in normal and ras-transformed cells. Biochimie
76: 792-800.
(7)
Mundschau L. J. and D. V. Faller. (1995) Platelet-derived growth factor signal transduction through the
interferon-inducible kinase PKR:
immediate early gene
induction. J. Biol. Chem. 270: 3100-3106.
(8)
Kasman, L. M. , Lukowiak, A., Garzcysnski, S., Youngman, P. and M.
Adang. (1998) Phage display of a biologically active Bacillus thuringiensis toxin. Appl.
Environ. Microbiol. 64(8): 2995-3003.
(9)
Kasman, L. M. & Volkman, L. E. (2000)
Filamentous actin is required for lepidopteran nucleopolyhedrovirus
progeny production. J. Gen. Virol. 81(7): 1881-1888.
(10) Kasman, L.M., Kasman, A., Westwater, C. Dolan, J.,
Schmidt, M.G., and Norris, J.S. (2002)
Overcoming the Phage replication threshold: a mathematical model with
implications for phage therapy. J. Virology 76(11):5557-5564.
(11)
Westwater C, Kasman, L.M., Schofield, D.A., Werner, P.A., Dolan, J.W.,
Schmidt, M.G. and Norris, J.S. (2003)
Use of genetically engineered phage to deliver antimicrobial agents to
bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob
Agents Chemother. 47(4):1301-7.
(12) Kasman,
L.M. (2005) CD13/Aminopeptidase
N and murine cytomegalovirus infection. Virology.
334(1):1-9.
(13) Kasman,
L.M. (2005) Barriers to coliphage infection of commensal bacteria of the
murine gastrointestinal tract. Virology
Journal 2005, 2:34 (15Apr2005)
(14) Kasman, L.M., Biber, J.M.
and Vroman, D.T. (2006) Immunoglobulin gene implicated in murine herpes stromal
keratitis is not associated with the human disease. Cornea 25(9): 1069-1071.
(15) Kasman,
LM, Ping,
L., Voelkel-Johnson, C. (2006) The histone deacetylase inhibitors
depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer
cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. Dec 22.
(16)
Pilgrim MJ, Kasman, L, Grewal, J, Bruorton ME, Werner P, London L, and
SD London. (2007) Salivary gland inoculation with attenuated MCMV: A Focused
Salivary Gland Infection with attenuated MCMV:
An Animal Model with Prevention of Pathology Associated with Systemic
MCMV Infection. Experimental and Molecular Pathology: Experimental and Molecular Pathology: 82 (3):269-279.
(17) White, S., Kasman,
L, Kelly, M, Lu, P, Spruill, L, McDermott, P, and Voelkel-Johnson, C. TRAIL
Sensitization of PC3
Prostate Cancer Cells by Doxorubicin is Characterized by Phosphorylation of
Elongation Factor 2
Upon Free Radical Generation. (In press).
(18) Kasman, LM., Pilgrim, MJ, London SD, London LL. 2007. Saliva deficiency independent of sialoadenitis in a mouse model of cytomegalovirus infection. (Submitted).
Non-Peer
Reviewed:
(1) Hamamdzic, D., Kasman, LM, and LeRoy, EC. (2002) Role of infectious
agents in Systemic Sclerosis. Current Opinion in Rheumatology.14:694-698.
(2) Kasman, L.M.,
Kasman, A., Westwater, C. Dolan, J., Schmidt, M.G., and Norris, J.S. (2002) Letter to the editor: Evidence for a phage replication
threshold? J. Virology 76(24):131123-131124.
Scholarly Books and Monographs: none
Chapters in Scholarly Books and Monographs:
(1) Greaser, M. L., K-M. Pan, J. D.
Fritz, L. J. Mundschau, and P. H.
Cooke. (1989) Molecular interactions of
contractile proteins. Proceedings of the International Symposium on
Food Quality and Biotechnology. Kung, S., D. D. Bills, and R. Quatrano, eds. (Butterworths, Boston)
pp.181-200.
Peer Reviewed Electronic Publications:
none
Non-Peer Reviewed Electronic Publications:
none
Other Publications:
(1) Kasman, L.M.,
Kasman, A., Westwater, C. Dolan, J., Schmidt, M.G., and Norris, J.S.,
Schofield, D.A. Genetically engineered phage and the use of genetically
engineered phage to deliver nucleic acid to bacteria. U.S. and International Patent Application
PCT/US03/06941, March 6, 2003.
(2) Kasman, L.M.,
Kasman, A., Westwater, C. Dolan, J., Schmidt, M.G., and Norris, J.S. Overcoming the Phage replication threshold: a
mathematical model with implications for phage therapy. U.S. Provisional Patent Application,
60/372,892, 15 April 2002.
(3) Findeis, M.
A., H. Benjamin, M. B. Garnick, M. L. Gefter, A. Hundal, L. Kasman, G. Musso, M.J.
Reed, E. R. Signer, and J. Wakefield. . Assignee: Praecis Pharmaceuticals, Inc.
(Cambridge, MA)Modulators of ß-amyloid peptide aggregation. United States
Patent 6,319,498. November 20, 2001
(4)
Kasman, L. M. and M. Adang. Phage display of a biologically active Bacillus thuringiensis toxin. U. S. Patent Application. August 2000.
(5) Findeis, M.
A., H. Benjamin, M. B. Garnick, M. L. Gefter, A. Hundal, L. Kasman, G. Musso, M. J.
Reed, E. R. Signer, and J. Wakefield. . Assignee: Praecis Pharmaceuticals, Inc.
(Cambridge, MA) Modulators of ß-amyloid peptide aggregation. United States
Patent 5,854,215 December 29, 1998
(6) Findeis, M.
A., H. Benjamin, M. B. Garnick, M. L. Gefter, A. Hundal, L. Kasman, M. Kelley, W.
Kubasek, S. Molineaux, G. Musso, M.J. Reed, E. R. Signer, and J. Wakefield.
Assignee: Praecis Pharmaceuticals, Inc. (Cambridge, MA)A.beta. peptides that
modulate ß--amyloid aggregation. United States Patent 5,854,204 December 29, 1998
(7) Findeis, M.
A., H. Benjamin, M. B. Garnick, M. L. Gefter, A. Hundal, L. Kasman, J.-J. Lee, S.
Molineaux, G. Musso, E. R. Signer, M.J. Reed, and J. Wakefield. Assignee:
Praecis Pharmaceuticals, Inc. (Cambridge, MA)
A.beta. peptides that modulate ß--amyloid aggregation. United States
Patent 5,817,626 October 6, 1998